Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement

American Journal of Cardiology

Volumn 85, Issue 5, 2000, Pages 664-665

  Grogan, Martha ^a   Gertz, Morie A ^a   Kyle, Robert A ^a   Tajik, A Jamil ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AMYLOIDOSIS; ARTICLE; BIOPSY; CARDIOMYOPATHY; FEMALE; HEART MUSCLE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TIME;

AGED; AMYLOIDOSIS; BIOPSY; CARDIOMYOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; SURVIVAL RATE; TIME FACTORS;

EID: 0034153950     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00832-2     Document Type: Article

References (4)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
2. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207.
3. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999;93:1062-1066.
4. Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, de Macario EC, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. 5th ed. Washington DC: ASM Press, 1997:156-176.